Valneva and Cue Biopharma Secure New Funding via Private Placements to Boost Liquidity

Key Facts

Biotechnology firm Valneva SE has raised €37 million through a private placement of 15.8 million shares at €2.33 each, potentially generating another €47 million via warrants. Simultaneously, Cue Biopharma (CUE) secured $30 million in financing through its own private placement to bolster its financial position. While Valneva intends to use the proceeds to advance its clinical vaccine pipeline, CUE is navigating significant headwinds. Despite recent revenue growth, CUE faces persistent challenges regarding low financial strength and overall profitability. These capital raises highlight the ongoing reliance of biotech firms on private markets to fund intensive research and development. However, the issuance of new shares in both transactions typically results in immediate dilution for existing investors.

Version History